EBS compared with PBYI: revenue, margins and what each company keeps, and the suppliers and customers both name

EBSEmergent BioSolutions Inc.

Mkt capRevenueRevenue

PBYIPuma Biotechnology, Inc.

Mkt capRevenueRevenue

Compare

EBSEmergent BioSolutions Inc.

PBYIPuma Biotechnology, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only EBS 14

MGNXMacrogenicssupplier

SABSSAB Biotherapeuticscustomer

—Hikma Pharmaceuticalsunlistedsupplier

—Bardaunlistedcustomer

10 more · EBS chain ›

Shared 0

No shared counterparties.

Only PBYI 18

PFEPfizersupplier

CVSCVScustomer

MCKMcKessoncustomer

CAHCardinal Healthcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

14 more · PBYI chain ›

EBSEmergent BioSolutions Inc.

6.42▼−5.73%· post 6.42· delayed

Mkt cap$349.2MRevenue$234MQ2 FY26Revenue$743MFY25

PBYIPuma Biotechnology, Inc.

10.42▼−0.22%· post 10.17· delayed

After hoursNov 2 '26delayed

Mkt cap$538.9MRevenue$57MQ2 FY26Revenue$228MFY25

Compare

After hoursNov 2 '26delayed

EBSEmergent BioSolutions Inc.

PBYIPuma Biotechnology, Inc.

6.42▼−5.73%post 6.42delayed

Price

10.42▼−0.22%post 10.17delayed

$349.2M

Mkt cap

$538.9M

Q2 FY26$234M

Revenue

$57MQ2 FY26

FY25$743M

Revenue

$228MFY25

EBS6.42▼−5.73%vsPBYI10.42▼−0.22%After hoursNov 2 '26delayed